Breast cancer and endless research underway for the management and treatment of the same has sought attention across globe. I remember writing about the taking the right decisions around undergoing chemotherapy. The market has welcomed innovative products such as EndoPredict that helps to analyze the activity of 12 genes that are involved in the breast cancer. Essentially the kit provides the result in the form of a EPclin score which is interpreted to understand the recurrence of breast cancer.
The success of EndoPredict, backs the recommendation that came from NICE which suggests that it is highly recommended to get the gene expression testing done. Non profit organizations such as NCCN, ESMO, ASCO and AGO also suggest the importance of testing the tissue that shall predict the chances of cancer recurrence.
Additionally, the kit also helps to cater to questions such as,
– What are the chances of my cancer coming back in the next ten years?
– Can I forgo taking chemotherapy?
– Will I need hormone therapy after 5 years?
Needless to say, these guidelines further promote and authenticate the benefits and use of EndoPredict amongst the cancer patients. This is expected to massively contribute to better management of breast cancer across the globe. EndoPredict is only test which has a holistic approach and includes molecular fingerprint of the tumor along with the clinicopathological parameters, and provides the most definitive classification of risk category.
Also, being a second generation breast cancer recurrence test it has superior molecular components due to which it can very well predict the late metastasis i.e 5-15 years recurrence.